Tabletbehandling giver markant bedre og nemme
Merck Serono’s Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial •Two-year primary efficacy endpoint of CLARITY trial met: 58% relative…